BiotechTube

Clopidogrel treatment group

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 50/100
50
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease

Trial Timeline

Mar 22, 2023 → Dec 31, 2031

NCT ID
NCT05845489

About Clopidogrel treatment group

Clopidogrel treatment group is a approved stage product being developed by Yuhan for Coronary Artery Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05845489. Target conditions include Coronary Artery Disease.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)
✅EvolocumabHeartFlowApproved
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅statins, ezetimibe + Combination therapyYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅Prasugrel + ClopidogrelDaiichi SankyoApproved
✅30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved

Hype Score Breakdown

Clinical
20
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05845489ApprovedRecruiting

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
ExenatideEli LillyPhase 3
40
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
40
statins, ezetimibe + Combination therapyYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21
PrasugrelDaiichi SankyoApproved
43
ADP receptor inhibitorsDaiichi SankyoPre-clinical
26
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
35
prasugrel + clopidogrelDaiichi SankyoPhase 1
29
Prasugrel + ClopidogrelDaiichi SankyoApproved
43
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
47
Placebo + PrasugrelDaiichi SankyoPhase 3
40
30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
50